Cannabis and Prostate Cancer
No clinical trials show cannabis treats prostate cancer; evidence exists only for symptom support.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis cells-in-a-dish research looks real—cannabinoids do trigger prostate cancer cell death in labs. But zero human trials have tested whether that translates to living patients. Where cannabis actually has evidence is managing nausea, pain, and anxiety during chemotherapy or ADT. That's legitimate and worth discussing with your oncology team. The 'cannabis cures cancer' narrative online is marketing; people who delayed proven treatments for oil protocols have died.
Not medical advice
This article is not medical advice. It is a plain-language summary of published research. Prostate cancer is treatable and often curable when caught early and managed properly. If you have prostate cancer or suspect you do, work with a urologist and oncologist. Tell them about any cannabis use—it can interact with chemotherapy, hormonal therapy, and anesthesia. Do not substitute cannabis for treatments that have decades of survival data behind them based on internet claims, including this one.
Plain-language summary
Prostate cancer cells, like many cancer cell types, carry cannabinoid receptors (CB1 and CB2). In laboratory dishes and in mice, THC, CBD, and synthetic cannabinoids can slow prostate cancer cell growth, trigger cell death (apoptosis), and reduce androgen receptor activity Strong evidence[1][2][3].
What does not exist: a single completed, published randomized clinical trial showing that cannabis or any cannabinoid treats prostate cancer in living humans No data. The leap from a cell culture dish to a human tumor is enormous, and most cancer drugs that look promising in cells fail in trials.
Where cannabis has actual human evidence is in supportive care—managing symptoms and side effects during conventional treatment. That is a real and legitimate role, but it is not 'treating the cancer.'
What probably works
Chemotherapy-induced nausea and vomiting (CINV). Cannabinoids—specifically oral THC (dronabinol) and synthetic nabilone—are FDA-approved for chemo-related nausea that doesn't respond to first-line drugs Strong evidence[4]. This is not prostate-specific; it applies to patients receiving docetaxel or cabazitaxel for metastatic prostate cancer. The FDA approval is specific to these two cannabinoid products for this indication.
Cancer-related pain. Nabiximols (Sativex, a THC/CBD oral spray) has moderate evidence for adjunct pain control in advanced cancer, though results in recent large trials have been less impressive than in older studies Weak / limited[5]. Inhaled or oral cannabis is widely used for cancer pain with patient-reported benefit, though high-quality controlled data is limited Weak / limited.
Sleep and anxiety during treatment. Survey and observational data consistently show cancer patients report improved sleep and reduced anxiety with cannabis Weak / limited[6]. Randomized controlled trials are sparse. See also THC Dose and Anxiety and Cannabis and PTSD for related evidence.
What might work
Appetite and cachexia. THC stimulates appetite in some cancer patients, but randomized trials in cancer-related weight loss have been underwhelming compared to its effect in HIV wasting Weak / limited[7]. See Cannabis and Cancer Cachexia for detailed review.
Direct anti-tumor effect. This is where the gap between online hype and evidence is widest. Preclinical data shows:
- THC and CBD induce apoptosis in LNCaP, PC-3, and DU-145 prostate cancer cell lines Strong evidence[1][2]
- Cannabinoids downregulate the androgen receptor in cell models [2]
- CB1 receptor expression is elevated in prostate tumor tissue and correlates with disease severity in some studies [3]
None of this has been translated into human clinical trial data. The preclinical signal is consistent enough to justify clinical trials, but those trials have not yet been completed or published No data.
What doesn't work or has weak evidence
Cannabis oil 'protocols' (Rick Simpson Oil, etc.) as monotherapy. There is no published clinical evidence that high-dose THC oil cures prostate cancer No data. Case reports circulate online but have not been verified, replicated, or published in peer-reviewed venues. Patients who delayed standard treatment in favor of unproven oil protocols have died of cancers that were likely curable with conventional surgery or radiation.
CBD alone as a cancer treatment. Despite marketing claims, no human data supports CBD monotherapy for prostate cancer No data.
Cannabis preventing prostate cancer. A small number of observational studies have examined cannabis use and prostate cancer incidence, with inconsistent results—some suggesting lower risk, others no association Disputed[8]. The data quality is poor (self-reported use, uncontrolled confounders).
Strain type predicting cancer symptom relief. Indica, sativa, and hybrid labels have little botanical meaning and do not predict effects reliably. Cannabinoid and terpene profiles (chemotype) matter more. See Cannabis and Cancer Overview for more.
What we don't know
- Whether any cannabinoid, at any dose, slows prostate cancer progression in humans.
- Whether cannabinoids interact safely with androgen deprivation therapy (ADT), the backbone of advanced prostate cancer treatment.
- Optimal ratios, doses, or routes (oral, inhaled, sublingual) for symptom management in prostate cancer patients specifically; most data come from general oncology populations.
- Long-term effects of daily cannabis use during years of ADT, including effects on cardiovascular risk (already elevated in ADT patients) and cognition.
- Whether CBD's known inhibition of CYP3A4 and CYP2D6 enzymes meaningfully alters plasma levels of abiraterone, enzalutamide, or docetaxel in clinical practice Weak / limited[9].
- Interaction of THC or CBD with newer PSMA-targeted therapies or poly(ADP-ribose) polymerase (PARP) inhibitors.
Comparison with standard treatments
Standard prostate cancer treatments have decades of large randomized trial survival data backing them:
- Active surveillance for low-risk disease—excellent long-term outcomes, avoids over-treatment.
- Radical prostatectomy and radiation therapy—curative for localized disease in many patients.
- Androgen deprivation therapy (ADT)—extends survival in advanced and metastatic disease.
- Abiraterone, enzalutamide, docetaxel, cabazitaxel, Lu-177 PSMA, olaparib—each backed by randomized trials showing survival or progression-free survival benefit in specific disease contexts.
Cannabis has no clinical trial evidence for treating the disease itself. As an adjunct for symptom management during treatment, it sits alongside other supportive medications (ondansetron for nausea, opioids for pain, mirtazapine for appetite, sleep aids) — sometimes helpful, not first-line for most indications, and worth discussing with the treating oncologist. See Cannabis and Cancer Pain and Medical Cannabis for Cancer Patients.
Risks and interactions
Drug interactions. CBD inhibits the liver enzymes CYP3A4 and CYP2D6. Several prostate cancer drugs—abiraterone and enzalutamide in particular—are metabolized by these pathways. Concurrent cannabis use can raise or lower drug levels, potentially reducing efficacy or increasing toxicity Weak / limited[9]. Discuss with your oncology team before combining. See Cannabis and Polypharmacy Risks.
Cardiovascular effects. ADT increases cardiovascular risk. Smoked cannabis acutely raises heart rate and blood pressure and is associated with elevated myocardial infarction risk in vulnerable patients Weak / limited[10]. Vaporization or edibles reduce but do not eliminate this concern.
Falls, cognition, and bone health. Older patients (median prostate cancer diagnosis is around age 67) are at higher fall risk with cannabis use. ADT itself causes bone loss; cannabis effects on bone metabolism are understudied. Cognitive effects are dose- and person-dependent. See Cannabis and Working Memory.
Inhalation of combustion products. Smoking cannabis carries respiratory risks similar to tobacco smoke; long-term pulmonary effects are documented but less severe than cigarettes on a per-use basis Weak / limited. Vaporization or edibles avoid this route. See Cannabis Smoke vs Tobacco Smoke.
Delay of effective treatment. This is the single biggest risk. Prostate cancers caught early are often curable with surgery or radiation. Cancers caught late are often not curable. Using unproven cannabis protocols in place of timely biopsy, staging, or definitive therapy can be fatal.
Interaction with anesthesia. Chronic cannabis use can affect anesthetic requirements and post-operative recovery. Tell the surgical team if you use cannabis regularly.
How to talk to your oncology team
Oncologists and urologists are generally not judgmental about cannabis use. What they need to know:
- How much, how often, and what form. Specify THC and CBD content if known (from lab testing or product label).
- Why you're considering it. Nausea, pain, sleep, anxiety—each has different first-line options, and cannabis may or may not be the best fit.
- Other medications. Full drug list is essential to catch CYP interactions.
- Your concerns about conventional treatment. If you're hesitant about chemotherapy or surgery, say so. Your team can explain the evidence and options.
They want to manage interactions and avoid surprises during surgery or chemotherapy. Cannabis use will not disqualify you from treatment; withholding the information might.
Sources
- Peer-reviewed Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Research. 2005;65(5):1635–1641.
- Peer-reviewed De Petrocellis L, Ligresti A, Schiano Moriello A, et al. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. British Journal of Pharmacology. 2013;168(1):79–102.
- Peer-reviewed Chakravarti B, Ravi J, Ganju RK. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget. 2014;5(15):5852–5872.
- Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
- Peer-reviewed Boland EG, Bennett MI, Allgar V, Boland JW. Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive & Palliative Care. 2020;10(1):14–24.
- Peer-reviewed Pergam SA, Woodfield MC, Lee CM, et al. Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017;123(22):4488–4497.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al.; Cannabis-In-Cachexia-Study-Group. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome. Journal of Clinical Oncology. 2006;24(21):3394–3400.
- Peer-reviewed Sidney S. Marijuana use and cancer incidence (California, United States). Cancer Causes & Control. 1997;8(5):722–728.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–2809.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Breast Cancer — Laboratory findings are promising; clinical evidence for cancer treatment is absent. Sympt...
- Cannabis and Cancer Cachexia — Cannabis improves appetite reports, but has weak evidence for reversing muscle wasting.
- Cannabis and Cancer — Evidence-based overview of cannabis in cancer supportive care, symptom management, and doc...
- Cannabis and Cancer Pain — Evidence-based overview of cannabis medicines for cancer pain management.
- Cannabis and Cancer-Related Fatigue — Reviewing evidence that cannabis may help cancer fatigue indirectly, not as a direct treat...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Medical Cannabis for Cancer Patients — Cannabis can ease chemotherapy side effects; it does not cure cancer or replace standard t...
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...